Bruker Corporation (BRKR)

US — Healthcare Sector
Peers: IRTC  BTSG  GKOS  TMDX  KRYS  TFX  MMSI  CHE  TGTX  CRSP 

Automate Your Wheel Strategy on BRKR

With Tiblio's Option Bot, you can configure your own wheel strategy including BRKR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BRKR
  • Rev/Share 22.6086
  • Book/Share 16.5151
  • PB 2.431
  • Debt/Equity 0.7556
  • CurrentRatio 1.7296
  • ROIC -0.0148

 

  • MktCap 6010785960.0
  • FreeCF/Share 0.2849
  • PFCF 138.8172
  • PE -699.2
  • Debt/Assets 0.2995
  • DivYield 0.0051
  • ROE -0.004

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade BRKR Wolfe Research Peer Perform Outperform -- $60 Dec. 10, 2025
Initiation BRKR Goldman -- Sell -- $40 Dec. 9, 2025
Initiation BRKR Rothschild & Co Redburn -- Buy -- $60 Nov. 20, 2025
Downgrade BRKR Citigroup Buy Neutral -- $40 May 22, 2025
Initiation BRKR Guggenheim -- Buy -- $72 Dec. 19, 2024
Initiation BRKR UBS -- Neutral -- $66 Dec. 10, 2024
Upgrade BRKR Goldman Sell Neutral -- $60 Dec. 5, 2024
Initiation BRKR Barclays -- Overweight -- $75 Oct. 15, 2024
Downgrade BRKR Wolfe Research Outperform Peer Perform -- -- Sept. 30, 2024
Initiation BRKR Wells Fargo -- Overweight -- $78 Aug. 28, 2024

News

Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum
BRKR
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker's category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,.

Read More
image for news Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum
Bruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology
BRKR
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral

ST. LOUIS--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants. New releases in Bruker ProteoScape™, OmniScape™, and GlycoScape™ software now support database-independent PTM discovery, confident proteoform characterizatio.

Read More
image for news Bruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology
Don't Overlook Bruker (BRKR) International Revenue Trends While Assessing the Stock
BRKR
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Neutral

Examine the evolution of Bruker's (BRKR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Read More
image for news Don't Overlook Bruker (BRKR) International Revenue Trends While Assessing the Stock
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down
BRKR
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Negative

BRKR's Q4 EPS miss estimates as margins plunge and shares fall 2.7% despite a revenue beat, while the 2026 outlook targets 4%-5% sales growth.

Read More
image for news Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down
Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript
BRKR
Published: February 12, 2026 by: Seeking Alpha
Sentiment: Neutral

Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript

Read More
image for news Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript
Bruker (BRKR) Reports Q4 Earnings: What Key Metrics Have to Say
BRKR
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Bruker (BRKR) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Bruker (BRKR) Reports Q4 Earnings: What Key Metrics Have to Say
Bruker (BRKR) Q4 Earnings Miss Estimates
BRKR
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Negative

Bruker (BRKR) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.76 per share a year ago.

Read More
image for news Bruker (BRKR) Q4 Earnings Miss Estimates
Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
BRKR
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Negative

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for
Allspring Common Stock Fund Q4 2025 Performance Review
AAON, ALNT, BRKR, CHWY, EYE, HAE, KEX, RVLV, TDY
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Neutral

In the fourth quarter, Revolve's stock rose as its revenue met expectations with a 4.4% year-over-year increase. In fiscal second quarter 2026, Haemonetics delivered strong performance, raising guidance and posting margin gains that signal operational discipline. CHWY shares declined in September after the company reported elevated selling, general, and administrative expenses.

Read More
image for news Allspring Common Stock Fund Q4 2025 Performance Review
Artisan Small Cap Fund Q4 2025 Portfolio Activity
BRKR, CLBT, FLEX, GH, HXL, INSM, IRTC, ITGR, LASR, LSCC, PEN, SN
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Neutral

During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.

Read More
image for news Artisan Small Cap Fund Q4 2025 Portfolio Activity
Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BRKR
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral

Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Read More
image for news Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Should You Continue to Hold BRKR Stock in Your Portfolio?
BRKR
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Negative

Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.

Read More
image for news Should You Continue to Hold BRKR Stock in Your Portfolio?
RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI)
BRKR
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral

BERGISCH GLADBACH, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source of the Extreme Light Infrastructure – Nuclear Physics (ELI-NP) at the Horia Hulubei National Institute of Physics and Nuclear Engineering (IFIN-HH) in Romania. The total value of these ELI contracts is approximately €35 million (more than USD $40 million), w.

Read More
image for news RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI)
Bruker (BRKR) Up 17.1% Since Last Earnings Report: Can It Continue?
BRKR
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Bruker (BRKR) Up 17.1% Since Last Earnings Report: Can It Continue?
Bruker Corporation (BRKR) Q3 2025 Earnings Call Transcript
BRKR
Published: November 03, 2025 by: Seeking Alpha
Sentiment: Neutral

Bruker Corporation ( BRKR ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Joe Kostka Frank Laukien - Chairman, CEO & President Gerald Herman - Executive VP & CFO Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Avantika Dhabaria - BofA Securities, Research Division Tycho Peterson - Jefferies LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Joshua Waldman - Cleveland Research Company LLC Douglas …

Read More
image for news Bruker Corporation (BRKR) Q3 2025 Earnings Call Transcript
Earnings Preview: Bruker (BRKR) Q3 Earnings Expected to Decline
BRKR
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Negative

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Earnings Preview: Bruker (BRKR) Q3 Earnings Expected to Decline
Is the Options Market Predicting a Spike in Bruker Stock?
BRKR
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors need to pay close attention to BRKR stock based on the movements in the options market lately.

Read More
image for news Is the Options Market Predicting a Spike in Bruker Stock?
BRKR Shares Climb After Securing New Orders for Its NMR Systems
BRKR
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Bruker stock climbs after securing $10M in federally funded NMR orders from top U.S. research institutions.

Read More
image for news BRKR Shares Climb After Securing New Orders for Its NMR Systems
Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University
BRKR
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new orders for advanced Nuclear Magnetic Resonance (NMR) instrumentation from the New York Structural Biology Center (NYSBC), the University of Delaware and Northwestern University. Supported by the National Institutes of Health (NIH) and the National Science Foundation (NSF), these high-performance systems will enable leading research teams to pursue breakthroughs across a wide range of scientific research, dr.

Read More
image for news Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University
Bruker (BRKR) Up 3.6% Since Last Earnings Report: Can It Continue?
BRKR
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Bruker (BRKR) Up 3.6% Since Last Earnings Report: Can It Continue?
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
BRKR
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative

BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.

Read More
image for news Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
Unlocking Bruker (BRKR) International Revenues: Trends, Surprises, and Prospects
BRKR
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral

Explore Bruker's (BRKR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Read More
image for news Unlocking Bruker (BRKR) International Revenues: Trends, Surprises, and Prospects
Bruker Corporation (BRKR) Q2 2025 Earnings Call Transcript
BRKR
Published: August 04, 2025 by: Seeking Alpha
Sentiment: Neutral

Bruker Corporation (NASDAQ:BRKR ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Frank H. Laukien - Chairman, CEO & President Gerald N.

Read More
image for news Bruker Corporation (BRKR) Q2 2025 Earnings Call Transcript
Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
BRKR
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive

The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More
image for news Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Bruker (BRKR) Misses Q2 Earnings Estimates
BRKR
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Negative

Bruker (BRKR) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.52 per share a year ago.

Read More
image for news Bruker (BRKR) Misses Q2 Earnings Estimates
Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on August 4, 2025
BRKR
Published: July 21, 2025 by: Business Wire
Sentiment: Neutral

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the second quarter ended June 30, 2025 in a range of $795 - $798 million, which implies approximately flat reported revenue year-over-year. Bruker estimates that its non-GAAP organic revenue in the second quarter of 2025 declined approximately 7% year-over-year, with constant-exchange rate revenue declining approximately 3%. Second quarter 2025 bookings reflect weak academic demand, as w.

Read More
image for news Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on August 4, 2025
BRKR Stock Gains Following the Multi-System Advanced Packaging Order
BRKR
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Bruker ships and installs its 15th InSight WLI system as part of a 27-optical metrology unit order tied to AI chip packaging demand.

Read More
image for news BRKR Stock Gains Following the Multi-System Advanced Packaging Order
New Strong Sell Stocks for June 23rd
ARCC, BIDU, BRKR
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Negative

ARCC, BIDU and BRKR have been added to the Zacks Rank #5 (Strong Sell) List on June 23 2025.

Read More
image for news New Strong Sell Stocks for June 23rd
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
BRKR
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive

BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.

Read More
image for news Bruker Stock Set to Gain From Acquisition of Austria's biocrates
Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
BRKR
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis. Br.

Read More
image for news Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection

About Bruker Corporation (BRKR)

  • IPO Date 2000-08-04
  • Website https://www.bruker.com
  • Industry Medical - Devices
  • CEO Frank H. Laukien
  • Employees 11396

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.